# STROBE Statement—checklist of items that should be included in reports of observational studies

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1. (a) The study’s design with a commonly used term indicated in the abstract at the pages 1 and 2.  
(b) An informative and balanced summary of what was done and what was found provided in the abstract at pages 1 and 2. |
| **Introduction** | |
| Background/rationale | 2. The scientific background explained at pages 2 and 3. |
| Objectives | 3. Specific objectives, including any prespecified hypotheses stated in the introduction at the pages 2 and 3. |
| **Methods** | |
| Study design | 4. Key elements of study design presented early in the method at page 3. |
| Setting | 5. The setting, locations, and relevant dates, follow-up, and data collection described in the method at pages 3 and 4. |
| Participants | 6. The sources and methods of selection of all the falls and data given in the methods at pages 3 and 4. |
| Variables | 7. All outcomes, exposures, predictors, potential confounders, and effect modifiers clearly define at pages 4 and 5. |
| Data sources/ measurement | 8. The main data source is Swedish arthroplasty register as mentioned at page 3 as well as medical records as mentioned at page 5. Details of methods of assessment (measurement) described at pages 4 and 5. |
| Bias | 9. Efforts to address potential sources of bias described at page 5. |
| Study size | 10. The study size was based on data from the register as explained at pages 3 and 4. |
| Quantitative variables | 11. How quantitative variables were handled in the analyses explained at pages 4 and 5. |
| Statistical methods | 12. (a) Statistical methods, including those used to control for confounding described at page 5.  
(b) Methods used to examine subgroups and interactions described at page 5.  
(c) How missing data were addressed explained at pages 4 and 5.  
(d) *Cohort study*—It is an observational register study.  
*Cross-sectional study*—It is an observational register study.  
(e) There is no sensitivity analyses |

Continued on next page
Results
Participants 13
(a) Numbers of individuals at each stage of study reported at pages 3 and 4.
(b) Reasons for non-participation at each stage gives at pages 3 and 4.
(c) Flow diagram used, see figure 1.

Descriptive data 14
(a) Characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders gives at pages 6-8.
(b) Number of participants with missing data for each variable of interest indicated at pages 6 and 7.
(c) Cohort study—Follow-up time explained at page 6.

Outcome data 15
Cohort study—Numbers of outcome events reported at page 8.
Case-control study—Report numbers in each exposure category, or summary measures of exposure. It is an observational register study.
Cross-sectional study—Report numbers of outcome events or summary measures. It is a observational register study

Main results 16
(a) Unadjusted estimates and confounder-adjusted estimates and their precision (eg, 95% confidence interval) given at pages 6-9. Make clear which confounders were adjusted for and why they were included.
(b) Category boundaries when continuous variables were categorized reported as mentioned at page 7.
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period. It does not relevant.

Other analyses 17
Analyses of subgroups and interactions, and sensitivity analyses reported at pages 6-8.

Discussion
Key results 18
Key results with reference to study objectives summarised at pages 9 and 10.

Limitations 19
Limitations of the study discussed in the limitations section at page 11.

Interpretation 20
A cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence reported at pages 9-11.

Generalisability 21
Discuss the generalisability (external validity) of the study results.

Other information
Funding 22
The source of funding presented at page 6 and on completed disclosure form.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.